The aim of the present work was to formulate Zolmitriptan as orodispersible tablets by liquisolid systems technique and to evaluate the possibility of enhancing the rate of drug dissolution and in vivo absorption by such formulation to enhance bioavailability, also the aim to improve patient compliance suffering from migraine attack. The drug was dissolved in non- volatile vehicle propylene glycol (PG) and its solution was converted into dry- looking powder using liquisolid systems technology. The drug solution was absorbed onto microcrystalline cellulose (carrier material) and any excess liquid was adsorbed by colloidal silicon dioxide (coating material). The appropriate amounts of the liquisolid system components were calculated by measuring the flow properties of the systems containing three different superdisintegrants namely; croscarmellose sodium, sodium starch glycolate and crospovidone, each one with three different concentrations (2.5, 5, 7.5 %). The flow properties were measured using the angle of repose and the compressibility index. FT-IR showed that, there was no interaction between drug and the excipients. Liquisolid powder formula with suitable flowability and compressibilty was compressed into tablets. The main physical properties of the prepared tablets were found to comply with the pharmacopoeial requirements. The in vitro dissolution rate of Zolmitriptan was found to be enhanced from the prepared liquisolid orodispersible tablets compared to that from direct compressed orodispersible tablets. On storage, no significant differences between freshly prepared and stored tablets was found.